Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma
Status:
Not yet recruiting
Trial end date:
2026-09-29
Target enrollment:
Participant gender:
Summary
Open-label, Phase 1 Study of CD19 t-haNK as a Single Agent and in Combination With an IL-15
Superagonist (N-803) and Rituximab in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma.
Up to 20 subjects will be enrolled and randomized 1:1 to 1 of 2 cohorts, as outlined below.
The initial 3 subjects will be sequentially enrolled in a staggered fashion, with a 7 day
interval between each subject to enable the capture and monitoring of any acute and subacute
toxicities.